Entero Therapeutics Files 8-K for Unspecified Event
Ticker: GRDX · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: other-events, corporate-action
TL;DR
Entero Therapeutics filed an 8-K for an event on 6/25, but details are scarce.
AI Summary
Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on June 30, 2025, reporting an "Other Event" that occurred on June 25, 2025. The filing does not provide specific details about the event itself, only that it is being reported under Item 8.01 of the 8-K form.
Why It Matters
This filing indicates a significant event has occurred for Entero Therapeutics, but the lack of detail requires investors to seek further information to understand its implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, creating uncertainty about the nature and impact of the reported event.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- First Wave BioPharma, Inc. (company) — Former company name
- AzurRx BioPharma, Inc. (company) — Former company name
- BioPharma d'Azur, Inc. (company) — Former company name
- June 25, 2025 (date) — Date of earliest event reported
- June 30, 2025 (date) — Filing date
FAQ
What specific event is Entero Therapeutics, Inc. reporting on June 25, 2025?
The filing does not specify the nature of the 'Other Event' that occurred on June 25, 2025.
What is the significance of filing an 8-K under 'Other Events'?
Filing under 'Other Events' (Item 8.01) is typically for significant events that the company deems important enough to disclose but do not fit into the other specific categories of an 8-K.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on June 30, 2025.
What was Entero Therapeutics, Inc. formerly known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc.
Where is Entero Therapeutics, Inc. headquartered?
Entero Therapeutics, Inc. is headquartered at 777 Yamato Road, Suite 502, Boca Raton, Florida 33431.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Entero Therapeutics, Inc. (GRDX).